BioCentury | May 28, 2019
Company News

Management tracks: Atara names Novartis’ Touchon as CEO; plus Intellia, Arch Oncology

Atara Biotherapeutics Inc. (NASDAQ:ATRA) hired Pascal Touchon as president and CEO, effective June 24. He was global head cell & gene at Novartis AG (NYSE:NVS; SIX:NOVN), where he was responsible for the global launch of...
BioCentury | Oct 17, 2016
Clinical News

Kazano regulatory update

Japan approved an NDA from Takeda for Inisync alogliptin/metformin to treat Type II diabetes. The fixed-dose combination of alogliptin and metformin is approved as Kazano in the U.S. and as Vipdomet in the EU for...
BioCentury | Jun 1, 2015
Clinical News

Viberzi eluxadoline regulatory update

FDA approved an NDA for Viberzi eluxadoline from Actavis to treat irritable bowel syndrome with diarrhea (IBS-D). Actavis said the agency recommended the locally acting mu opioid receptor (MOR; OPRM1 ) agonist and delta opioid receptor...
BioCentury | May 18, 2015
Finance

Gassing up for royalties

Royalty Pharma has refilled its tank with a $1 billion equity raise and plans to use a portion of the money to ramp up its search for royalty streams from sources other than marketed products....
BioCentury | Sep 8, 2014
Clinical News

Eluxadoline regulatory update

FDA accepted and granted Priority Review to an NDA from Actavis for eluxadoline to treat diarrhea and abdominal pain in patients with diarrhea-predominant irritable bowel syndrome (IBS-D). The company said it plans to submit an...
BioCentury | Sep 3, 2014
Company News

Priority Review for Actavis' eluxadoline

FDA accepted and granted Priority Review to an NDA from Actavis plc (NYSE:ACT) for eluxadoline ( JNJ-270189066 ) to treat diarrhea and abdominal pain in patients with diarrhea-predominant irritable bowel syndrome (IBS-D). The company said it plans...
BioCentury | Jun 16, 2014
Company News

Aerocrine management update

Aerocrine AB (SSE:AERO), Solna, Sweden Business: Diagnostic Hired: Anders Murman as chief technology officer; and Marshall Woodworth as CFO, formerly CFO of Furiex Pharmaceuticals Inc. ; he succeeds Michael Colerus WIR Staff Diagnostic...
BioCentury | Jun 2, 2014
Clinical News

Nesina alogliptin regulatory update

Takeda said Japan's Ministry of Health, Labor and Welfare (MHLW) approved an application to expand the label of Type II diabetes drug Nesina alogliptin to include concomitant therapy with all oral anti-diabetic agents and insulin....
BioCentury | May 5, 2014
Finance

Pulling off the AZ gambit

Pfizer Inc. (NYSE:PFE) still has room to maneuver if it is really intent on using its bid for AstraZeneca plc (LSE:AZN; NYSE:AZN) to relocate in the more tax-friendly U.K. The trick is to provide enough...
BioCentury | May 5, 2014
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Acorda Therapeutics Inc. (NASDAQ:ACOR) fell $3.51 (10%) to $32.39 on Friday after FDA asked for an additional clinical trial in a complete response letter for Plumiaz diazepam nasal spray to treat acute repetitive...
Items per page:
1 - 10 of 101
BioCentury | May 28, 2019
Company News

Management tracks: Atara names Novartis’ Touchon as CEO; plus Intellia, Arch Oncology

Atara Biotherapeutics Inc. (NASDAQ:ATRA) hired Pascal Touchon as president and CEO, effective June 24. He was global head cell & gene at Novartis AG (NYSE:NVS; SIX:NOVN), where he was responsible for the global launch of...
BioCentury | Oct 17, 2016
Clinical News

Kazano regulatory update

Japan approved an NDA from Takeda for Inisync alogliptin/metformin to treat Type II diabetes. The fixed-dose combination of alogliptin and metformin is approved as Kazano in the U.S. and as Vipdomet in the EU for...
BioCentury | Jun 1, 2015
Clinical News

Viberzi eluxadoline regulatory update

FDA approved an NDA for Viberzi eluxadoline from Actavis to treat irritable bowel syndrome with diarrhea (IBS-D). Actavis said the agency recommended the locally acting mu opioid receptor (MOR; OPRM1 ) agonist and delta opioid receptor...
BioCentury | May 18, 2015
Finance

Gassing up for royalties

Royalty Pharma has refilled its tank with a $1 billion equity raise and plans to use a portion of the money to ramp up its search for royalty streams from sources other than marketed products....
BioCentury | Sep 8, 2014
Clinical News

Eluxadoline regulatory update

FDA accepted and granted Priority Review to an NDA from Actavis for eluxadoline to treat diarrhea and abdominal pain in patients with diarrhea-predominant irritable bowel syndrome (IBS-D). The company said it plans to submit an...
BioCentury | Sep 3, 2014
Company News

Priority Review for Actavis' eluxadoline

FDA accepted and granted Priority Review to an NDA from Actavis plc (NYSE:ACT) for eluxadoline ( JNJ-270189066 ) to treat diarrhea and abdominal pain in patients with diarrhea-predominant irritable bowel syndrome (IBS-D). The company said it plans...
BioCentury | Jun 16, 2014
Company News

Aerocrine management update

Aerocrine AB (SSE:AERO), Solna, Sweden Business: Diagnostic Hired: Anders Murman as chief technology officer; and Marshall Woodworth as CFO, formerly CFO of Furiex Pharmaceuticals Inc. ; he succeeds Michael Colerus WIR Staff Diagnostic...
BioCentury | Jun 2, 2014
Clinical News

Nesina alogliptin regulatory update

Takeda said Japan's Ministry of Health, Labor and Welfare (MHLW) approved an application to expand the label of Type II diabetes drug Nesina alogliptin to include concomitant therapy with all oral anti-diabetic agents and insulin....
BioCentury | May 5, 2014
Finance

Pulling off the AZ gambit

Pfizer Inc. (NYSE:PFE) still has room to maneuver if it is really intent on using its bid for AstraZeneca plc (LSE:AZN; NYSE:AZN) to relocate in the more tax-friendly U.K. The trick is to provide enough...
BioCentury | May 5, 2014
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Acorda Therapeutics Inc. (NASDAQ:ACOR) fell $3.51 (10%) to $32.39 on Friday after FDA asked for an additional clinical trial in a complete response letter for Plumiaz diazepam nasal spray to treat acute repetitive...
Items per page:
1 - 10 of 101